178,377 results

#105677-AAV5

Ready-to-use AAV5 particles produced from pAAV_hSyn1-SIO-stGtACR2-FusionRed (#105677). In addition to the viral particles, you will also receive purified pAAV_hSyn1-SIO-stGtACR2-FusionRed plasmid DNA. Synapsin-driven, Cre-dependent, soma-targeted anion-conducting channelrhodopsin fused to FusionRed for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Ofer Yizhar

Mahn et al Nat Commun. 2018 Oct 8;9(1):4125. doi: 1

Oct. 21, 2024

Academic Institutions and Nonprofits only

#199777-PHPeB

Ready-to-use AAV PHP.eB particles produced from AiP13781 - pAAV-AiE0452h-minBG-iCre(R297T)-BGHpA (Alias: CN3781) (#199777). In addition to the viral particles, you will also receive purified AiP13781 - pAAV-AiE0452h-minBG-iCre(R297T)-BGHpA (Alias: CN3781) plasmid DNA. Cre recombinase expression in striatal indirect pathway medium spiny neurons (D2-MSNs). These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Allen Institute for Brain Science, Jonathan Ting

Hunker et al Neuron. 2025 May 21;113(10):1507-1524.e1

July 15, 2024

Academic Institutions and Nonprofits only

#178329-AAV1

Ready-to-use AAV1 particles produced from pAAV.hSyn.iGluSnFR3.v857.PDGFR (#178329). In addition to the viral particles, you will also receive purified pAAV.hSyn.iGluSnFR3.v857.PDGFR plasmid DNA. Synapsin-driven, third generation glutamate sensor iGluSnFR3, variant 857. These AAV preparations are suitable purity for injection into animals.

Kaspar Podgorski

Aggarwal et al Nat Methods. 2023 May 4. doi: 10.1038/s4

May 16, 2023

Academic Institutions and Nonprofits only